Q-omics provides the consensus-scored CLRN1 profile across patient tissues and cancer cell-line models. CLRN1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CLRN1 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, CLRN1 RNA expression shows 6,528 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, KIRC, and STAD as cancer lineages where CLRN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLRN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLRN1 survival associations across molecular data types. CLRN1 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLRN1 RNA expression–survival associations across cancer types. High CLRN1 expression shows unfavorable associations in MESO, COAD, BLCA, LGG and HNSC, but favorable associations in BRCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for CLRN1 RNA expression.
This table summarizes CLRN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CLRN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLRN1 shows higher tumor expression in KIRC, BRCA, LIHC and CHOL. The KIRC box plot shows higher CLRN1 RNA expression in tumor versus normal tissue (log2 FC = +0.017, t-test p < 0.001).
This table shows molecular features associated with CLRN1 in patient tissues and cancer cell lines. In patient samples, CLRN1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CLRN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LUNG_SCLC.
